Erasmus Medical Center

The goal of gene therapy for severe hemophilia A patients is to decrease the annual bleed rate (ABR) and reduce the treatment burden of frequent prophylactic Factor VIII infusions, but hematologists a

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GSK Teams With Ideaya On Synthetic Leth

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . BeiGene Reacquires Tislelizu

Edwards Lifesciences’ Sapien 3 On October 15 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, Howard Hermann, MD, from the University of Pennsylvania presented